You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: 8,129,343

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,129,343 protect, and when does it expire?

Patent 8,129,343 protects OZEMPIC, WEGOVY, and RYBELSUS, and is included in three NDAs.

This patent has forty-two patent family members in twenty-two countries.

Summary for Patent: 8,129,343

Title:	Acylated GLP-1 compounds
Abstract:	Protracted GLP-1 compounds and therapeutic uses thereof.
Inventor(s):	Lau; Jesper (Farum, DK), Bloch; Paw (Taastrup, DK), Hansen; Thomas Kruse (Herlev, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	11/908,834
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,129,343
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 8,129,343

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS	⤷ Sign Up
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-004	Oct 6, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS	⤷ Sign Up
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS	⤷ Sign Up
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-003	Mar 28, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS	⤷ Sign Up
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-001	Jun 4, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-002	Jun 4, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-003	Jun 4, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,129,343

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	05102171	Mar 18, 2005

PCT Information
PCT Filed	March 20, 2006	PCT Application Number:	PCT/EP2006/060855
PCT Publication Date:	September 21, 2006	PCT Publication Number:	WO2006/097537

International Family Members for US Patent 8,129,343

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1863839	⤷ Sign Up	300936	Netherlands	⤷ Sign Up
European Patent Office	1863839	⤷ Sign Up	2018C/016	Belgium	⤷ Sign Up
European Patent Office	1863839	⤷ Sign Up	CR 2018 00019	Denmark	⤷ Sign Up
European Patent Office	1863839	⤷ Sign Up	122018000075	Germany	⤷ Sign Up
European Patent Office	1863839	⤷ Sign Up	2018/017	Ireland	⤷ Sign Up
European Patent Office	1863839	⤷ Sign Up	22/2018	Austria	⤷ Sign Up
European Patent Office	1863839	⤷ Sign Up	1890018-3	Sweden	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.